13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
71 檔
19.8%
At the close of Q2 2025, Birchview Capital, LP disclosed equity holdings valued at approximately $213.8M, spread across 71 reported holdings.
Birchview Capital, LP executed strategic sector rebalancing during Q2 2025, establishing 12 new positions while fully exiting 9 holdings and trimming 13 positions.
In terms of portfolio concentration, the top 5 core holdings (including BMY, KLAC, CORT) accounted for 19.8% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 14.86% | -2.56% | -52.81% | |
| 2 | KLAC | Kla CORP | Stock-Tech | 14.10% | +8.51% | — | |
| 3 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 4.90% | +1.25% | +1.82% | |
| 4 | OVV | Ovintiv Inc | Stock-Energy | 4.06% | -0.98% | +105.94% | |
| 5 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 4.02% | -0.15% | -28.70% | |
| 6 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.86% | +0.10% | +2.31% | |
| 7 | PHR | Phreesia Inc | Stock-Other | 3.24% | -0.07% | EXIT | |
| 8 | PRTA | Prothena Corporation plc | Stock-Other | 2.72% | -0.42% | +35.45% | |
| 9 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.63% | -0.09% | -0.00% | |
| 10 | STOK | Stoke Therapeutics Inc | Stock-Other | 2.37% | -1.16% | -0.00% | |
| 11 | ELUT | Elutia Inc | Stock-Other | 2.28% | -0.02% | -2.41% | |
| 12 | CSTL | Castle Biosciences Inc | Stock-Other | 2.24% | -0.04% | +25.11% | |
| 13 | QDELUSD | Quidelortho CORP | Stock-Other | 2.08% | -0.04% | +7.29% | |
| 14 | EQT | Eqt CORP | Stock-Energy | 2.01% | -0.39% | — | |
| 15 | HROW | Harrow Inc | Stock-Other | 1.82% | — | -17.71% | |
| 16 | NVCR | NovoCure Limited | Stock-Healthcare | 1.79% | -1.26% | EXIT | |
| 17 | AXGN | Axogen Inc | Stock-Other | 1.73% | — | — | |
| 18 | ✓ | Biodesix Inc | Stock-Other | 1.61% | +0.65% | — | |
| 19 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.51% | +0.28% | -25.36% | |
| 20 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.45% | -0.13% | — | |
| 21 | ALKS | Alkermes plc | Stock-Healthcare | 1.42% | +0.22% | — | |
| 22 | MASI* | Masimo CORP | Stock-Other | 1.38% | — | -26.60% | |
| 23 | QURE | uniQure N.V. | Stock-Other | 1.37% | +0.15% | +11.27% | |
| 24 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.21% | -0.38% | -43.33% | |
| 25 | DCGO | Docgo Inc | Stock-Other | 1.19% | — | -11.57% | |
| 26 | TMCI | Treace Medical Concepts Inc | Stock-Other | 1.03% | — | +7.28% | |
| 27 | SLDB | Solid Biosciences Inc | Stock-Other | 0.86% | +0.54% | +38.83% | |
| 28 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.82% | — | -0.02% | |
| 29 | FCX | Freeport-mcmoran Inc | Stock-Materials | 0.78% | -0.07% | — | |
| 30 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.75% | -0.65% | EXIT | |
| 31 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.74% | -2.14% | — | |
| 32 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.69% | -0.43% | EXIT | |
| 33 | OMGBP | Outset Medical Inc | Stock-Other | 0.66% | -0.22% | EXIT | |
| 34 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.65% | -0.11% | — | |
| 35 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.65% | -0.74% | EXIT | |
| 36 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.62% | +0.11% | — | |
| 37 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.57% | -0.70% | — | |
| 38 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.56% | — | — | |
| 39 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.56% | -0.08% | — | |
| 40 | KIDS | Orthopediatrics CORP | Stock-Other | 0.55% | — | +30.00% | |
| 41 | IMNM | Immunome Inc | Stock-Other | 0.55% | -0.12% | — | |
| 42 | XNCR | Xencor Inc | Stock-Other | 0.55% | — | +169.23% | |
| 43 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.52% | +0.85% | — | |
| 44 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.49% | -0.07% | — | |
| 45 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.46% | — | — | |
| 46 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.37% | — | — | |
| 47 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.36% | — | — | |
| 48 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.36% | — | — | |
| 49 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.34% | — | — | |
| 50 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.33% | +0.07% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | KLAC | Kla CORP | +14.1% | NEW | New buy |
| 2 | OVV | Ovintiv Inc | +2.1% | +105.94% | Add |
| 3 | NVCR | NovoCure Limited | +1.3% | +225.81% | Add |
| 4 | STOK | Stoke Therapeutics Inc | +1.2% | -0.00% | Trim |
| 5 | NBIX | Neurocrine Biosciences Inc | +1% | +2.31% | Add |
| 6 | FCX | Freeport-mcmoran Inc | +0.8% | NEW | New buy |
| 7 | GPCR | Structure Therapeutics Inc | +0.7% | NEW | New buy |
| 8 | CSTL | Castle Biosciences Inc | +0.7% | +25.11% | Add |
| 9 | PHR | Phreesia Inc | +0.7% | — | Unchanged |
| 10 | PTGX | Protagonist Therapeutics Inc | +0.6% | -0.00% | Trim |
| 11 | OLMA | Olema Pharmaceuticals Inc | +0.6% | NEW | New buy |
| 12 | NTLA | Intellia Therapeutics Inc | +0.6% | NEW | New buy |
| 13 | IMNM | Immunome Inc | +0.6% | NEW | New buy |
| 14 | QURE | uniQure N.V. | +0.6% | +11.27% | Add |
| 15 | PACB | Pacific Biosciences Of Calif | +0.5% | NEW | New buy |
| 16 | FHTX | Foghorn Therapeutics Inc | +0.5% | — | Unchanged |
| 17 | SLDB | Solid Biosciences Inc | +0.5% | +38.83% | Add |
| 18 | APGE | Apogee Therapeutics Inc | +0.4% | +100.00% | Add |
| 19 | OMGBP | Outset Medical Inc | +0.4% | +40.68% | Add |
| 20 | EQT | Eqt CORP | +0.4% | — | Unchanged |
| 21 | XNCR | Xencor Inc | +0.3% | +169.23% | Add |
| 22 | COGT | Cogent Biosciences Inc | +0.3% | NEW | New buy |
| 23 | PHAT | Phathom Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 24 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.2% | -0.02% | Trim |
| 25 | ACAD | Acadia Pharmaceuticals Inc | +0.2% | -28.70% | Trim |
| 26 | BBIO | Bridgebio Pharma Inc | +0.2% | NEW | New buy |
| 27 | RARE | Ultragenyx Pharmaceutical In | +0.2% | +12.50% | Add |
| 28 | TELA | Tela Bio Inc | +0.1% | — | Unchanged |
| 29 | HROW | Harrow Inc | +0.1% | -17.71% | Trim |
| 30 | 2655787D | Blueprint Medicines CORP | +0.1% | — | Unchanged |
| 31 | KIDS | Orthopediatrics CORP | +0.1% | +30.00% | Add |
| 32 | MLTX | Moonlake Immunotherapeutics | +0.1% | — | Unchanged |
| 33 | SRRK | Scholar Rock Holding CORP | +0.1% | — | Unchanged |
| 34 | BCRX | Biocryst Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 35 | APLT | Applied Therapeutics Inc | +0.1% | NEW | New buy |
| 36 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.1% | -0.00% | Trim |
| 37 | ATEC | Alphatec Holdings Inc | +0.1% | — | Unchanged |
| 38 | INBX | Inhibrx Biosciences Inc | +0.1% | — | Unchanged |
| 39 | ZBIO | Zenas Biopharma Inc | +0.1% | — | Unchanged |
| 40 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 41 | GOSS | Gossamer Bio Inc | 0% | — | Unchanged |
| 42 | QDELUSD | Quidelortho CORP | 0% | +7.29% | Add |
| 43 | ✓ | Aptevo Therapeutics Inc | 0% | NEW | New buy |
| 44 | VTYXUSD | Ventyx Biosciences Inc | 0% | — | Unchanged |
| 45 | KPTIEUR | Karyopharm Therapeutics Inc | 0% | — | Unchanged |
| 46 | CGEM | Cullinan Therapeutics Inc | 0% | — | Unchanged |
| 47 | AXSM | Axsome Therapeutics Inc | 0% | — | Unchanged |
| 48 | CADL | Candel Therapeutics Inc | 0% | — | Unchanged |
| 49 | NPCE | Neuropace Inc | — | — | Unchanged |
| 50 | IFRX | InflaRx N.V. | — | — | Unchanged |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 71 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
KLAC
市值: $14.2M
Top Position Liquidated / Trimmed
SWTXUSD
前期市值: $365.4K
During Q2 2025, Birchview Capital, LP's top holdings by market value included BMY (14.9%)、KLAC (14.1%)、CORT (4.9%). The largest single position, BMY, represented 14.9% of total portfolio value.
In Q2 2025, Birchview Capital, LP made 49 total portfolio adjustments, initiating 12 new buys, adding to 15 positions, trimming 13 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.